Cargando…

Acute Migraine Prescription Patterns Vary by Baseline Cardiovascular Risk and Clinical Characteristics: A Real-World Evidence Study

INTRODUCTION: Migraine is a debilitating neurological disease and one of the most common disorders in the world. Although the triptans, potent 5-HT1B/1D receptor agonists, are an effective and widely used acute treatment of migraine, few studies have assessed how their cardiovascular risk warnings c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Hu, Vincent, Maurice, Zhang, Xiang, Dennehy, Ellen B., Goodloe, Robert, Aurora, Sheena K., Smith, Timothy R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7648791/ https://www.ncbi.nlm.nih.gov/pubmed/32328974 http://dx.doi.org/10.1007/s40122-020-00167-3

Ejemplares similares

Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019)

Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data
por: Dodick, David W., et al.
Publicado: (2020)

Exciting excitable brains: an update on migraine pathophysiology
por: Aurora, Sheena K.
Publicado: (2003)

The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics
por: Karlsson, William Kristian, et al.
Publicado: (2023)

Machine prescription for chronic migraine
por: Stubberud, Anker, et al.
Publicado: (2022)

Real-World Economic Impact of OnabotulinumtoxinA in Patients With Chronic Migraine
por: Rothrock, John F, et al.
Publicado: (2014)

Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States
por: McAllister, Peter, et al.
Publicado: (2021)

Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
por: Driessen, Maurice T., et al.
Publicado: (2022)

Potential Channeling Bias in the Evaluation of Cardiovascular Risk: The Importance of Comparator Selection in Observational Research
por: Li, Hu, et al.
Publicado: (2022)

Nasal Delivery of Acute Medications for Migraine: The Upper Versus Lower Nasal Space
por: Martin, Vincent, et al.
Publicado: (2021)

Exercise Prescription Guidelines for Cardiovascular Disease Patients in the Absence of a Baseline Stress Test
por: Mytinger, Megan, et al.
Publicado: (2020)

CGRP and the Trigeminal System in Migraine
por: Iyengar, Smriti, et al.
Publicado: (2019)

Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study
por: Gladstone, Jonathan, et al.
Publicado: (2021)

Real-world economic impact of onabotulinumtoxina in patients with chronic migraine
por: Rothrock, JF, et al.
Publicado: (2013)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

The migraine signature study: Methods and baseline results
por: Pressman, Alice R., et al.
Publicado: (2020)

Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
por: Lo, Siu Hing, et al.
Publicado: (2022)

Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine
por: Tsai, Max, et al.
Publicado: (2021)

Real world preventative drug management of migraine among Spanish neurologists
por: García-Azorin, D., et al.
Publicado: (2019)

A prospective real-world analysis of erenumab in refractory chronic migraine
por: Lambru, Giorgio, et al.
Publicado: (2020)

Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE
por: Alsaadi, Taoufik, et al.
Publicado: (2022)

The evaluating prescription opioid changes in veterans (EPOCH) study: Design, survey response, and baseline characteristics
por: Krebs, Erin E., et al.
Publicado: (2020)

Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies
por: Aurora, Sheena K., et al.
Publicado: (2016)

Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review
por: Martin, Vincent, et al.
Publicado: (2020)

Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?
por: Annoni, Giorgio, et al.
Publicado: (2016)

Correction to: Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine
por: Ament, Michael, et al.
Publicado: (2021)

Improving the detection of chronic migraine: Development and validation of Identify Chronic Migraine (ID-CM)
por: Lipton, Richard B, et al.
Publicado: (2015)

Low-dose Aspirin for Primary Prevention of Cardiovascular Events in Postmenopausal Women with Type-2 Diabetes: The Prescriptive Approach in the Real World
por: Maiello, Maria, et al.
Publicado: (2021)

Real-World Analysis of Remote Electrical Neuromodulation (REN) for the Acute Treatment of Migraine
por: Ailani, Jessica, et al.
Publicado: (2022)

A real‐world, observational study of erenumab for migraine prevention in Canadian patients
por: Becker, Werner J., et al.
Publicado: (2022)

Real-world evidence of galcanezumab for migraine treatment in Japan: a retrospective analysis
por: Takizawa, Tsubasa, et al.
Publicado: (2022)

Predictors of galcanezumab response in a real-world study of Korean patients with migraine
por: Kim, Seung Ae, et al.
Publicado: (2023)

Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study
por: Ohtani, Seiya, et al.
Publicado: (2023)

Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials
por: Shapiro, Robert E., et al.
Publicado: (2019)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Patients’ Baseline Characteristics, but Not Tocilizumab Exposure, Affect Severe Outcomes Onset in Giant Cell Arteritis: A Real-World Study
por: Dumain, Cyril, et al.
Publicado: (2022)

A Real-world Study on Prescription Pattern of Fosfomycin in Critical Care Patients
por: Zirpe, Kapil G, et al.
Publicado: (2021)

Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
por: Davies, Brendan, et al.
Publicado: (2017)

Real-world opioid use among patients with migraine enrolled in US commercial insurance and risk factors associated with migraine progression
por: Shao, Qiujun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7mtjkc4jm7782ia882p6c9sjd3